Rare Genetic Drivers of Lethal Prostate Cancer

Alexander W. Wyatt

doi:10.1001/jamaoncol.2023.3352

糖心vlog

Editorial

September 21, 2023

Rare Genetic Drivers of Lethal Prostate Cancer

Alexander W.聽Wyatt,聽BSc, DPhil^1,2

Author Affiliations Article Information

¹Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
²Michael Smith Genome Sciences Centre, British Columbia Cancer, Vancouver, British Columbia, Canada

JAMA Oncol. 2023;9(11):1499-1501. doi:10.1001/jamaoncol.2023.3352

Genetic testing is a recently adopted standard of care for male patients with metastatic or high-risk localized prostate cancer.¹ Rare deleterious germline alterations in a small number of cancer-associated genes are relevant for clinical management and/or selection of systemic therapy.² The most well-known prostate cancer predisposition gene is BRCA2, with deleterious germline BRCA2 variants strongly associated with poor prognosis across the spectrum of disease, and also conferring sensitivity to poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors in the metastatic castration-resistant setting.³^,4 The genes TP53, ATM, MSH2, and several other genes directly or indirectly linked with DNA damage repair processes are also associated with clinically-aggressive prostate cancer and/or response to PARP inhibitors or immune checkpoint inhibitors.²^,5

糖心vlog

Object moved to here.

糖心vlog

Rare Genetic Drivers of Lethal Prostate Cancer

Others Also Liked

Featured Articles

USPSTF Recommendation Statements

Blogs

糖心vlog

Object moved to here.

糖心vlog

Select Your Interests

Rare Genetic Drivers of Lethal Prostate Cancer

See More About

Citation

Manage citations:

Others Also Liked